Zacks Investment Research·5 days ago
Are Medical Stocks Lagging BillionToOne, Inc. (BLLN) This Year?Here is how BillionToOne (BLLN) and Concentra Group (CON) have performed compared to their sector so far this year.
BillionToOne, Inc.(BLLN)Earnings, Financials & Key Ratios
BLLN•NASDAQ
$118.04
1853.1× P/E·Price updated Jul 7, 2026
- Revenue$305M+100.0%
- EBITDA$16M+145.2%
- Net Income$7M+117.9%
- EPS (Diluted)0.06+106.8%
- Gross Margin68.32%+28.8%
- EBITDA Margin5.25%+122.6%
- Operating Margin5.25%+117.0%
- Net Margin2.44%+109.0%
- ROE2.3%+105.5%
BLLN Price & Volume
BillionToOne, Inc. (BLLN) stock price & volume — 10-year historical chart
Loading chart...
Rapid Diagnostic Scaling Drives Profitable Revenue Growth
Investment Thesis • Updated 2026Q1
VerdictPositive
Growth:Accelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Improving
Primary Risk:Rapid Scaling Execution Risk
Key Thesis Takeaways
- BillionToOne has successfully transitioned from a loss-making startup to a profitable diagnostic entity, evidenced by a 2026Q1 net income of $18.0 million.
- The company's ability to scale revenue to $108.4 million while expanding gross margins to 73.0% suggests a highly efficient operational model.
- However, investors should monitor the $14.5 million working capital outflow in 2026Q1, which may indicate potential cash conversion challenges as the company continues its aggressive market expansion.
Verdict Logic
the company has achieved a successful profitability inflection with $18.0 million in net income and a forward P/E of 120.04, reflecting strong growth prospects despite the inherent risks of rapid diagnostic scaling.
BLLN Growth Metrics
BillionToOne, Inc. (BLLN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-25.19%
5 Years-25.19%
3 Years-25.19%
Last Year3.73%
BLLN Recent Earnings
BillionToOne, Inc. (BLLN) EPS & revenue vs analyst estimates — last 3 quarters
●Beat EPS 2/3 qtrs (67%)●Beat Revenue 3/3 qtrs (100%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.34+981.8%
$0.03
Rev
$108M+11.6%
$97M
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.11+57.1%
$0.07
Rev
$96M+10.2%
$87M
Q4 2025
Dec 9, 2025Metric
Actual
Est
EPS
$0.10-28.3%
$0.14
Rev
$84M+0.8%
$83M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.34vs $0.03+981.8% | $108Mvs $97M+11.6% |
| Q2 2026 | Mar 4, 2026 | $0.11vs $0.07+57.1% | $96Mvs $87M+10.2% |
| Q4 2025 | Dec 9, 2025 | $0.10vs $0.14-28.3% | $84Mvs $83M+0.8% |
Based on last 3 quarters of dataView full earnings history →
Latest BLLN News
Recent stock market news and headlines for BillionToOne, Inc. (BLLN)
GuruFocus·Jun 29, 2026
BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed StudyBillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer
PRNewsWire·Jun 29, 2026
BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed StudyTissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor types and two prospective cohorts MENLO PARK, Calif., June 29, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the publication of Longitudinal Methylated ctDNA Increases Predict Immunotherapy Progression Across Solid Tumors , a peer-reviewed study demonstrating that Northstar Response® was a stronger predictor of survival than standard-of-care imaging in patients with advanced solid tumors receiving immunotherapy or immunotherapy combination therapy, and that the addition of molecular monitoring to imaging provided greater predictive power than imaging alone.
Peers Comparison
Key metrics vs top competitors for BillionToOne, Inc. (BLLN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $118.04 | $5.43B | 1853.06 | 99.97% | 2.44% | 2.3% | — | |
| $281.27 | $40.28B | -185.05 | 35.9% | -9.05% | -15.13% | — | |
| $191.76 | $29.13B | 35.19 | -0.78% | 19.43% | 32.84% | — | |
| $30.78 | $2.41B | 47.35 | 10.4% | 5.23% | 13.34% | — | |
| $28.31 | $1.46B | -70.78 | 13.79% | -1.98% | -2.61% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — |
Compare BLLN vs Peers
BillionToOne, Inc. (BLLN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BLLN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BLLN Frequently Asked Questions
BillionToOne, Inc. (BLLN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is BillionToOne, Inc.'s revenue?
BillionToOne, Inc. (BLLN) reported $354.5M in revenue for fiscal year 2025. This represents a 394% increase from $71.7M in 2023.
How fast is BillionToOne, Inc. growing?
BillionToOne, Inc. (BLLN) grew revenue by 100.0% over the past year. This is strong growth.
Is BLLN profitable?
Yes, BillionToOne, Inc. (BLLN) is profitable, generating $25.2M in net income for fiscal year 2025 (2.4% net margin).
Dividend & Returns
What is BLLN's return on equity?
BillionToOne, Inc. (BLLN) has a return on equity (ROE) of 2.3%. This is below average, suggesting room for improvement.
What is BillionToOne, Inc.'s free cash flow?
BillionToOne, Inc. (BLLN) generated $28.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.